Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Alpha Cognition Inc C.ACOG

Alternate Symbol(s):  ACOG

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.


CSE:ACOG - Post by User

Post by stockpatrolon Oct 01, 2021 7:13pm
168 Views
Post# 33956639

Alpha Cognition Announces Scientific Advisory Board

Alpha Cognition Announces Scientific Advisory Board
Alpha Cognition Announces Scientific Advisory Board… And A Big Shareholder Awareness Campaign... Also Announces $14.4M Financing Is Closed!... It’s GO TIME!
 
7 highly accredited and respected professionals have joined the scientific advisory board for $ACOG.V. Together they have decades of experience in Dementia, Alzheimer’s, brain injury and trauma. They have been well rounded experience in front line work, education, studies & trials. Just as important of an announcement imo, is a big marketing budget ($250USD) to target new shareholders.
https://www.businesswire.com/news/home/20211001005039/en/Alpha-Cognition-Announces-Formation-and-Members-of-Scientific-Advisory-Board-and-Investor-Relations-Agreements 
 
I already believe that ACOG is several undervalued as they are in clinic trials with FDA. If successful, Alpha 1062, could be the most important drug to help slow and treat brain disease and injury. I believe this could naturally be a #multibagger, but with marketing to help tell the story I’m even more confident. I am a shareholder who just bought this week and last around $1.30. ACOG just closed $14.4M (this is a 15% increase to the original $12.5M that was announced), and done at $1.50 (currently trading at a ~10% discount in the mid $1.30s)
https://www.newsfilecorp.com/release/98239
<< Previous
Bullboard Posts
Next >>